72 related articles for article (PubMed ID: 8070310)
1. In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A.
Ring BJ; Parli CJ; George MC; Wrighton SA
Drug Metab Dispos; 1994; 22(3):352-7. PubMed ID: 8070310
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
3. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.
Ekström G; Gunnarsson UB
Drug Metab Dispos; 1996 Sep; 24(9):955-61. PubMed ID: 8886604
[TBL] [Abstract][Full Text] [Related]
4. Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans.
Franz PM; Mattiuz EL; Hatcher BL; DeSante KA; Breau AP; Occolowitz JL; Dorman DE; Schmid CR; Goldberg MJ; Rubin A
Drug Metab Dispos; 1993; 21(2):249-54. PubMed ID: 8097693
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
Obach RS
Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
[TBL] [Abstract][Full Text] [Related]
6. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.
Lin JH; Chiba M; Chen IW; Nishime JA; Vastag KJ
Drug Metab Dispos; 1996 Dec; 24(12):1298-306. PubMed ID: 8971134
[TBL] [Abstract][Full Text] [Related]
7. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes.
Harrell AW; Wheeler SM; Pennick M; Clarke SE; Chenery RJ
Drug Metab Dispos; 1993; 21(1):18-23. PubMed ID: 8095215
[TBL] [Abstract][Full Text] [Related]
8. Chronic toxicity, metabolism, and pharmacokinetics of the 5-HT3 receptor antagonist zatosetron (LY277359) in Fischer 344 rats.
Bendele AM; Buenger DA; McGrath JP; Schmalz CA; Hanasono GK
Fundam Appl Toxicol; 1994 May; 22(4):494-504. PubMed ID: 8056197
[TBL] [Abstract][Full Text] [Related]
9. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
Witherow LE; Houston JB
J Pharmacol Exp Ther; 1999 Jul; 290(1):58-65. PubMed ID: 10381760
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
11. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
12. Ethosuximide is primarily metabolized by CYP3A when incubated with isolated rat liver microsomes.
Sarver JG; Bachmann KA; Zhu D; Klis WA
Drug Metab Dispos; 1998 Jan; 26(1):78-82. PubMed ID: 9443857
[TBL] [Abstract][Full Text] [Related]
13. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
Chauret N; Tremblay N; Lackman RL; Gauthier JY; Silva JM; Marois J; Yergey JA; Nicoll-Griffith DA
Anal Biochem; 1999 Dec; 276(2):215-26. PubMed ID: 10603245
[TBL] [Abstract][Full Text] [Related]
14. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A).
Yasumori T; Chen L; Nagata K; Yamazoe Y; Kato R
J Pharmacol Exp Ther; 1993 Jan; 264(1):89-94. PubMed ID: 8423554
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of DHEA by cytochromes P450 in rat and human liver microsomal fractions.
Fitzpatrick JL; Ripp SL; Smith NB; Pierce WM; Prough RA
Arch Biochem Biophys; 2001 May; 389(2):278-87. PubMed ID: 11339818
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
17. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of phencyclidine by human liver microsomes.
Laurenzana EM; Owens SM
Drug Metab Dispos; 1997 May; 25(5):557-63. PubMed ID: 9152594
[TBL] [Abstract][Full Text] [Related]
19. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
20. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
Nebbia C; Ceppa L; Dacasto M; Carletti M; Nachtmann C
Drug Metab Dispos; 1999 Sep; 27(9):1039-44. PubMed ID: 10460804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
